

HIV DART 2004

FRONTIERS IN DRUG DEVELOPMENT
FOR ANTIRETROVIRAL THERAPIES

Preliminary Program

Sunday, December 12

Chairs Joep Lange, University of Amsterdam, the Netherlands
 Raymond F Schinazi, Emory University/VA Medical Center, USA

15:00 Opening Remarks and Introduction
 Joep Lange, University of Amsterdam, the Netherlands

David Barry DART Achievement Award

15:15 Inhibitors of HIV-integrase: past, present and future
 Daria Hazuda, Merck Research Laboratories, USA

STATE OF THE ART LECTURES

Pathogenesis and Mechanism of HIV Disease: Implications for Therapeutic Strategies

16:00 Pathogenesis of drug-resistant HIV: implications for treatment strategies
 Steven Deeks, University of California, San Francisco, USA

16:45 Viral strategies for persistence in the face of antiretroviral and immune pressure
 Mario Stevenson, University of Massachusetts Medical School, USA

19:30 – 21:30 Welcome Reception

Monday, December 13

MORNING SESSION

Gertrude Elion Distinguished Lecturer Award

- Chairs Daria Hazuda, Merck Research Laboratories, USA
 Julio Montaner, St. Paul's Hospital, Canada
- 8:00 Presentation of Gertrude Elion distinguished lecturer award
 Robert Murphy, Northwestern University, USA
- 8:10 The era of antiretroviral therapy: how it started and evolved
 Erik De Clercq, Rega Institute for Medical Research, K.U. Leuven, Belgium

Drug Discovery and Development: Entry Blockers and Anti-Sense Approaches

- 9:00 HIV attachment inhibitors – a novel class of antiretrovirals in clinical development
 Richard Colonna, Bristol-Myers Squibb, USA
- 9:20 CCR5 receptor antagonist SCH-417690: a new class of potent HIV therapy
 Lisa Dunkle, Schering-Plough Research Institute, USA
- 9:40 UK-427,857: A novel small molecule CCR5 receptor antagonist
 Howard Mayer, Pfizer Global Research and Development, USA
- 10:00 Morning Break
- 10:30 Impaired antigen presentation by CD4 T cells and its therapeutic implications
 Franco Lori, Research Institute for Genetic and Human Therapy (RIGHT), USA
- 10:40 Establishing safety in the clinic for an HIV-1 based viral vector expressing anti-HIV
 antisense in autologous T lymphocytes
 Boro Dropulic, VIRxSYS Corporation, USA
- 10:50 Panel Discussion

Drug Discovery and Development: Gag Processing and Capsid Assembly Inhibitors

- 11:20 Maturation inhibition: a new class of potent HIV inhibitors that disrupts core
 condensation by targeting a late step in GAG processing
 David Martin, Panacos Pharmaceuticals, Inc., USA
- 11:40 AlphaHGA; an new antiviral substance against HIV affecting capsid assembly
 Anders Vahlne, Karolinska Institutet, Sweden
- 11:50 Panel Discussion
- 12:30 Lunch Break

MONDAY EVENING SESSION

Preventive Technologies: Immunology and Microbicides

- Chairs Mario Stevenson, University of Massachusetts Medical School, USA
 Zeda Rosenberg, International Partnership for Microbicides, Inc., USA
- 17:30 Progress in microbicide development
 Zeda Rosenberg, International Partnership for Microbicides, Inc., USA
- 17:50 Recent development in the use of immunomodulators in HIV
 Richard Pollard, UC Davis Medical Center, USA
- 18:10 DermaVir therapeutic immunization to control HIV viral load
 Julianna Lisziewicz, Research Institute for Genetic and Human Therapy (RIGHT), USA
- 18:30 Panel Discussion

Tuesday, December 14

MORNING SESSION

The Implications of Viral Drug Resistance for the Development of Antiretroviral Agents and the Management of Patients

- Chairs Erik De Clercq, Rega Institute for Medical Research, K.U. Leuven, Belgium
Brendan Larder, RDI, UK
- 8:00 Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases
Eddy Arnold, Rutgers University, USA
- 8:20 Insights into molecular mechanisms of drug resistance for HIV-1 reverse transcriptase
Karen Anderson, Yale University School of Medicine, USA
- 8:40 Predicting HIV treatment response using neural network models
Brendan Larder, RDI, UK
- 9:00 HIV protease inhibitors: what is left to do?
John Erickson, Sequoia Pharmaceuticals, USA
- 9:20 The Tat protein of HIV-1 is methylated at arginine residues and this regulates HIV gene expression
Mark Wainberg, McGill University AIDS Centre, Canada
- 9:40 A CCR5 inhibitor AK602/ONO4128/GW873140 potent against HIV-1, its CCR5 binding profile and the synergy with other anti-HIV-1 agents
Hiroaki Mitsuya, National Cancer Institute, USA
- 9:50 Synthesis and antiviral activity of cyclobutyl nucleoside analogs
Dennis Liotta, Emory University, USA
- 10:00 Resistance profile of human immunodeficiency virus to mannose-binding proteins
Jan Balzarini, Rega Institute for Medical Research, Belgium
- 10:10 Panel Discussion
- 10:40 Morning Break

Clinical Resistance

- 11:00 Prevention of viral drug resistance
Douglas Richman, University of California, San Diego/VA Medical Center, USA
- 11:20 Optimizing the use of genotypic resistance testing in clinical practice
Julio Montaner, St. Paul's Hospital, Canada
- 11:40 Reverset resistance profile
Robert Murphy, Northwestern University, USA

- 11:50 Most highly treatment-experienced recipients of Tipranavir/Ritonavir (TPV/r) achieve inhibitory quotients (IQ) that are associated with large week-24 viral load (VL) reductions
Hernan Valdez, Boehringer Ingelheim Pharmaceuticals, Inc., USA
- 12:00 Tipranavir (TPV) mutation score predicts virologic success in PI-experienced HIV-positive adults
Veronika Kohlbrenner, Boehringer Ingelheim Pharmaceuticals, Inc., USA
- 12:10 Panel Discussion
- 12:40 Lunch Break (***ON YOUR OWN TO ENJOY THE PROPERTY***)

TUESDAY EVENING SESSION

Viral Dynamics and Pharmacogenomics Symposium

- Chairs Mark Wainberg, McGill University AIDS Centre, Canada
 Jean-Pierre Sommadossi, Idenix Pharmaceuticals, Inc., USA
- 16:00 Poster Reception, with wine and hors d'oeuvres**
- 17:30 Pharmacogenetics and pharmacogenomics
 Amalio Telenti, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland
- 17:50 The use of genotypic/phenotypic inhibitory quotient in patients with anti HIV treatment failure
 Christine Katlama, Hôpital de la Pitié-Salpêtrière, France
- 18:10 Viral and cellular dynamics in HIV-infected patients under treatment interruption driven by CD4 cell count
 Natalia Soriano-Sarabia, Virgen del Rocio University Hospital, Spain
- 18:20 Efficacy, resistance, fitness and replication capacity profiles of novel pyrimidinedione nonnucleoside inhibitors of HIV-1 and HIV-2
 Robert Buckheit, ImQuest BioSciences, USA
- 18:30 Panel Discussion

Wednesday, December 15

MORNING SESSION

Safety and Effectiveness of Antiretroviral Agents

First Line Therapy: Choices to achieve durability and managing metabolic complications

- Chairs** Robert Murphy, Northwestern University, USA
Douglas Richman, University of California, San Diego/VA Medical Center, USA
- 8:00 Future paradigm shifts in first-line therapy?
Daniel Kuritzkes, Brigham and Women's Hospital, USA
- 8:20 Toxicity and toxicity monitoring
Peter Reiss, NATEC Academic Medical Center, the Netherlands
- 8:40 May statins inhibit HIV-1 replication?
Bonaventura Clotet, Fundacio IRSI Caixa, Spain
- 9:00 Foscarnet used in salvage therapy of multidrug resistant HIV-1 infected patients
Christine Katlama, Hôpital de la Pitié-Salpêtrière, France
- 9:10 Safety and efficacy of Nelfinavir-based HAART during pregnancy: a retrospective review
Melanie Hopkins, Pfizer, Inc., USA
- 9:20 Needle-free administration of Enfuvirtide with Biojector(TM) 2000 (B2000) demonstrates pharmacokinetic bioequivalence to standard needle administration
Diego Miralles, Trimeris, Inc, USA
- 9:30 Panel Discussion
- 10:15 Morning Break

Salvage and Alternative Therapies

- Chairs** Christine Katlama, Hôpital de la Pitié-Salpêtrière, France
Amalio Telenti, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland
- 10:45 Determinants of therapy success
Joep Lange, University of Amsterdam, the Netherlands
- 11:05 Treatment of ART-experienced patients with detectable viremia during therapy
Schlomo Staszewski, Klinikum der JW Goethe University, Germany
- 11:25 Twenty-four week combined analysis of the Tipranavir (TPV) RESIST studies of 1483 treatment-experienced patients given either Tipranavir/Ritonavir (TPV/r) or an optimized standard of care regimen using one of four Ritonavir-boosted comparator PIs (CPI/r)
Scott McCallister, Boehringer Ingelheim Pharmaceuticals, Inc., USA

- 11:35 Sustained virologic and immunologic response over 120 weeks in antiretroviral therapy (ART)-naïve subjects receiving Fosamprenavir/Ritonavir (FPV/r) QD
Joseph Gathe, Therapeutic Concepts, P.A., USA
- 11:45 1-(β-D-Dioxolane)thymine is active against a variety of clinically relevant NRTI drug resistant HIV-1 strains
Chung K. Chu, University of Georgia, USA
- 11:55 Panel Discussion
- 12:30 Lunch Break

WEDNESDAY EVENING SESSION

Struggles to get Antiviral Agents to Market

17:30 Challenges for implementation of clinical and operational research in developing countries
Sandra Nusinoff Lehrman, National Institutes of Health, USA

17:50 Struggles to get Antiviral Agents to Market: Panel Discussion

Moderators: Kris Thiessen, Helix Management, USA
Sherry Knowles, King & Spalding, USA

Invited Panelists: Paul Friedman, Incyte Corporation, USA
Jean-Pierre Sommadossi, Idenix Pharmaceuticals, Inc., USA
Howard Mayer, Pfizer Global Research and Development, USA
Sandra Nusinoff Lehrman, National Institutes of Health, USA
Dani Bolognesi, Trimeris, Inc, USA

20:00 Gala Party

Thursday, December 16

MORNING SESSION

HIV/Hepatitis and Other Co-Infections

- Chairs Yves Benhamou, Hôpital Pitié-Salpêtrière, France
Carol Brosgart, Gilead Sciences, USA
- 8:00 Impact of antiretroviral therapy on liver patients coinfecting with HCV and HIV
Yves Benhamou, Hôpital Pitié-Salpêtrière, France
- 8:20 When and how to treat HIV/HBV co-infection?
Bruce Polsky, St. Luke's-Roosevelt Hospital Center, USA
- 8:40 HIV/HBV co-infection
Carol Brosgart, Gilead Sciences, USA
- 9:00 Progress with Telbivudine for hepatitis B and NM283 for hepatitis C
Nathaniel Brown, Idenix Pharmaceuticals, Inc., USA
- 9:20 Tb/HIV coinfection
Renee Ridzon, Bill & Melinda Gates Foundation, USA
- 9:40 Safety, efficacy, and tolerability of Nelfinavir (NFV) containing antiretroviral therapy (ART) for patients on methadone maintenance co-infected with HIV and hepatitis C viruses
Steven Kritz, Addiction Research and Treatment Corporation, USA
- 9:50 Panel Discussion
- 10:20 Morning Break

Closing Session – Late Breaker Session

- 10:50 The RNAi story
- 11:10 Probing host-pathogen interactions with insertional mutagenesis and siRNA
Tom Hodge, Centers for Disease Control and Prevention, USA
- 11:30 Panel Discussion
- 12:00 Closing Remarks**